TD Cowen raised the firm’s price target on Revvity (RVTY) to $124 from $120 and keeps a Buy rating on the shares. The firm noted shares weakened following its Q4 release after a positive preannouncement, in part given the 2H-weighted margin and EPS trajectory in the guide. Cowen said the the 2H skew doesn’t change their positive view for continued Dx strength, pre-clinical pharma recovery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target raised to $118 from $112 at Evercore ISI
- Revvity price target raised to $118 from $115 at Barclays
- Revvity: Undervalued Mid-Growth Name with Clear Margin Expansion Path Drives Buy Rating
- Revvity Earnings Call: Solid Execution, Cautious 2026 Outlook
- Revvity price target raised to $105 from $100 at Jefferies